Discover an informative webinar delving into commercial manufacturing in messenger RNA (mRNA) clinical therapies, new capacity installations and unique partnering models in commercial manufacturing. mRNA and cell/gene therapies represent cutting-edge approaches in the realm of biomedicine, with a focus on innovative disease targeting and treatment. These fields are rapidly evolving, characterized by intricate landscapes, and share common challenges that demand inventive solutions for their development, scaling and eventual commercialization.
In this webinar, the featured speaker will discuss new capacity installations and unique partnering models and provide key updates on their progress toward commercial manufacturing of plasmid DNA (pDNA), mRNA, lipid nanoparticle (LNP) and fill/finish.
At BIOVECTRA, the immense power of flexibility to revolutionize the future of medicine is harnessed. They are advancing unique technologies that leverage their platform and customized manufacturing solutions and are designed to overcome supply chain complexities, capacity constraints and scalability challenges, which are key limitations to success.
Join this webinar to gain insights into commercial manufacturing in mRNA clinical therapies and the challenges and inventive solutions for development, scaling and commercialization.
Jessica Madigan, Director Business Development, Nucleic Acid Modalities, BIOVECTRA
Jessica Madigan has a BSc in Chemistry with 15+ years of experience focused on nucleic acid manufacturing and development. Jessica played a key role at start-up CDMO leading to the successful launch of mRNA, plasmid, capping analogs and modified nucleotide products. Jessica also holds a Project Management Professional (PMP) Certification and successfully managed over 30 API manufacturing projects for mRNA early-phase clinical trials. Since joining BIOVECTRA in 2022, Jessica has supported business development efforts for pDNA, mRNA, LNP formulation and fill/finish services.
Who Should Attend?
This webinar will appeal to:
- Tech Ops
- Quality assurance
- Category Managers
What You Will Learn
Attendees will gain insights into:
- The rapidly evolving landscapes of mRNA and cell/gene therapies and the common challenges they share
- How innovative solutions are driving the development, scaling, and commercialization of these therapies
- New capacity installations, unique partnering models and the progress towards commercial manufacturing of pDNA, mRNA, LNP and fill/finish
- Benefits of using optimized/established manufacturing processes
- Strategies to overcome common challenges in analytical testing of product and product purity
BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.